---
title: "What is the current Omnicell stock price and historical performance?"
site: "hygiea.tech"
kind: "qa"
author: "hygiea.tech"
date: "November 21, 2026"
canonical: "https://hygiea.tech/knowledge/what_is_the_current_omnicell_stock_price_and_historical_performance.php"
markdown: "https://hygiea.tech/knowledge/what_is_the_current_omnicell_stock_price_and_historical_performance.php/index.md"
description: "Omnicell Inc. shares have endured a severe valuation contraction, trading approximately forty-two percent below fair value as of early August 2026..."
---

# What is the current Omnicell stock price and historical performance?

hygiea.tech · November 21, 2026

> Omnicell Inc. shares have endured a severe valuation contraction, trading approximately forty-two percent below fair value as of early August 2026...

## Omnicell Stock Price Snapshot

Omnicell Inc. shares have endured a severe valuation contraction, trading approximately forty-two percent below fair value as of early August 2026. This steep decline follows a broader market slump that erased roughly seventy-eight percent of the stock’s price since late September. Despite this heavy depreciation, analysts at Zacks Premium identified the healthcare technology firm as a strong value candidate in mid-November. The publication highlighted the company’s potential for long-term momentum, suggesting that the recent price collapse may present a strategic entry point for investors willing to wait out the volatility. The sharp drop in share price reflects broader concerns about weak guidance issued by management earlier in the year, which weighed heavily on investor sentiment throughout the summer months.

**Also worth reading:** [How Does Healthcare Waste Compliance ROI Transform Safety-Ops Performance?](https://hygiea.tech/knowledge/how_does_healthcare_waste_compliance_roi_transform_safety-ops_performance.php) · [How does Omnicell use its net cash to challenge Pyxis?](https://hygiea.tech/knowledge/how_does_omnicell_use_its_net_cash_to_challenge_pyxis.php) · [Why is Cardinal Health considered suitable for current market conditions?](https://hygiea.tech/knowledge/why_is_cardinal_health_considered_suitable_for_current_market_conditions.php)

The disconnect between the depressed stock price and the bullish analyst ratings underscores a complex investment narrative. While the shares have plummeted, the underlying business model remains focused on B2B healthcare hygiene and compliance operations. Investors are now weighing the tangible risks of the guidance shortfall against the perceived undervaluation flagged by research teams. The momentum argument relies on the belief that the market has overreacted to short-term financial signals. As November progresses, traders are watching closely to see if the stock can stabilize near these historical lows. The current trading range offers a stark contrast to earlier valuations, forcing a reevaluation of risk tolerance for those holding positions in the healthcare tech sector.

## Historical Price Trends Analysis

Omnicell Inc. shares have endured a severe valuation correction, plunging 78 percent by mid-September 2026. This dramatic slump pushed the stock below fair value estimates, a trend that intensified as August approached. Analysts noted the shares traded roughly 42 percent under intrinsic worth on the heels of weak guidance, signaling deep investor skepticism about near-term growth. The financial narrative shifted rapidly from caution to potential opportunity as the quarter progressed. By late November, the stock repositioned itself as a strong value play, attracting renewed attention from research platforms. Zacks Premium highlighted the ticker as a compelling entry point for investors seeking to build confidence through disciplined market participation. The momentum narrative gained traction again in early November, with analysts recommending the stock for long-term holds based on its current pricing dynamics. The rapid swing from a steep decline to a recognized value opportunity underscores the volatility inherent in healthcare technology equities. Investors watching the ticker must weigh the initial crash against the recent reclassification as a momentum asset. The data suggests a market struggling to find equilibrium between operational challenges and long-term strategic positioning. The current price reflects a complex interplay of past guidance misses and emerging analyst optimism.

The trajectory reveals a stock caught in a tug-of-war between fundamental weakness and technical recovery signals. The initial 78 percent drop created a significant overhang, yet the subsequent reclassification as a value stock suggests a floor may have formed. Weak guidance in August likely triggered the initial sell-off, but the shift toward momentum status by November indicates a change in sentiment. This duality requires careful navigation for those considering exposure. The market appears to be pricing in a scenario where operational improvements could eventually restore confidence. However, the historical context of such sharp declines warns against assuming stability. The current positioning relies heavily on future guidance rather than past performance. Investors must assess whether the recent momentum is sustainable or merely a short-term rebound. The stock’s journey from a steep underperformer to a recognized value candidate highlights the unpredictable nature of sector-specific equities. The key lies in monitoring upcoming earnings for proof of the touted turnaround. Until then, the price remains a reflection of speculative bets on long-term viability.

## Valuation And Fair Value

Omnicell Inc. shares traded below fair value following a severe seventy-eight percent slump that reshaped its market standing by late September 2026. Analysts flagged the stock as a strong value candidate in mid-November, noting that investors seeking confidence in volatile markets often find such depressed valuations compelling. The momentum narrative gained traction just days before the month ended, with reports highlighting the company as a top momentum pick for long-term holds. This shift suggests a complex interplay between fundamental weakness and speculative interest. The seventy-eight percent drop likely stemmed from broader sector pressures or specific operational headwinds, forcing a reevaluation of its intrinsic worth. Investors watching the ticker must weigh the apparent discount against the underlying business health. The recent classification as a value stock implies that the market has priced in significant pessimism, creating a potential entry point for those willing to absorb risk. The juxtaposition of a deep price decline with bullish momentum ratings creates a confusing but potentially lucrative environment for active traders.

By early August, the stock sat approximately forty-two percent below fair value estimates, driven by weak guidance that cast a shadow over near-term prospects. This discrepancy between trading price and analyst models highlights the uncertainty surrounding Omnicell’s operational trajectory. The guidance concerns likely stemmed from supply chain disruptions or slower adoption rates in healthcare hygiene and compliance sectors. Despite these headwinds, the company’s focus on B2B healthcare safety-ops SaaS positions it within a resilient industry. The wide gap between current pricing and fair value models suggests that the market may be overreacting to short-term negatives. Investors must scrutinize whether the weak guidance reflects temporary setbacks or structural issues within the business model. The subsequent recovery in momentum sentiment indicates that some market participants see value in the current discount. This divergence between fundamental valuation metrics and trading behavior underscores the importance of timing in this volatile segment.

## Recent Earnings And Guidance

Omnicell shares have endured a severe 78% slump that pushed the stock below fair value as of late September 2026. Analysts noted the stock traded roughly 42% below intrinsic worth following weak guidance issued in early August. This sharp decline reflects investor skepticism regarding the company’s near-term financial trajectory despite its position in the B2B healthcare hygiene sector. The market reaction underscores a disconnect between the firm’s operational focus on compliance and safety-ops SaaS and the broader sentiment driving its valuation. Recent headlines from November highlight conflicting narratives, with some sources labeling the stock a strong value play while others warn of continued downside risks. The divergence suggests uncertainty persists among institutional investors weighing the company’s long-term potential against immediate earnings disappointments.

By mid-November, momentum strategies began to emerge as a counterpoint to the bearish outlook. Reports from November 9 positioned Omnicell as a top momentum stock for long-term holders, signaling a shift in tactical interest. This pivot coincides with broader market dynamics where value seekers attempt to capitalize on the depressed price levels. The stock’s ability to attract momentum capital indicates a tentative recovery phase, though the underlying guidance concerns remain unresolved. Investors must navigate this tension between deep discounts and operational challenges. The coming months will reveal whether the company can translate its hygiene and compliance offerings into tangible earnings growth that justifies the current valuation. Until then, the stock remains a battleground between value proponents and cautious observers tracking the guidance revisions.

## Future Growth Momentum

Omnicell shares have endured a severe 78% slump, trading significantly below intrinsic value as of late September 2026. This dramatic contraction reflects deep market skepticism surrounding weak corporate guidance, with analysts flagging the stock as potentially 42% undervalued just weeks prior. The relentless downward pressure stems from broader concerns about growth sustainability in the healthcare technology sector, forcing investors to reassess long-term viability amid shifting operational realities.

Recent commentary from Zacks Premium highlights the company’s emerging status as a strong value play, suggesting that the steep decline may present a strategic entry point for patient capital. By late November, the narrative shifted toward momentum, with analysts identifying Omnicell as a top long-term hold for those willing to weather short-term volatility. The divergence between the harsh valuation metrics and the renewed bullish outlook underscores a critical inflection point. Investors must weigh the tangible risk of continued underperformance against the potential for a sharp rebound if underlying business fundamentals stabilize. The current price action signals a tense standoff between bearish sentiment driven by past guidance failures and growing confidence in the company’s ability to execute its strategic roadmap. This tension defines the immediate trading environment, leaving room for significant price discovery as new data emerges.

## Omnicell (OMCL) Key Metrics

| Metric | Value | Context |
| --- | --- | --- |
| Current Price | $14.50 | NASDAQ: OMCL |
| Recent Slump | -78% | As of Sept 22, 2026 |
| Fair Value Gap | 42% Below | Weak guidance noted |
| Analyst Rating | Strong Value | Zacks Premium assessment |

Omnicell shares retreated sharply in late 2026, trading roughly 42% below fair value on August 3rd due to weak guidance. A deeper 78% slump persisted through September, leaving the stock deeply discounted. Despite this heavy decline, analysts flagged the ticker as a strong value play by mid-November. The momentum thesis suggests long-term potential, though current valuation metrics reflect significant investor skepticism regarding near-term operational performance.

## Quick answers

### Why did Omnicell stock drop 78% recently?

The slump reflects broader market corrections and specific concerns regarding weak revenue guidance issued by the company.

### Is Omnicell stock currently undervalued?

Analysts suggest the stock trades significantly below fair value, presenting a potential opportunity for value-oriented investors.

### When are Omnicell's next earnings results?

Third-quarter results are scheduled to be released before markets open on October 29th following the earnings call.

### What makes Omnicell a momentum stock?

Long-term momentum is driven by its strong position in B2B healthcare hygiene and compliance SaaS solutions.

Canonical: https://hygiea.tech/knowledge/what_is_the_current_omnicell_stock_price_and_historical_performance.php
Markdown: https://hygiea.tech/knowledge/what_is_the_current_omnicell_stock_price_and_historical_performance.php/index.md

```json
{"@context":"https://schema.org","@type":"QAPage","headline":"What is the current Omnicell stock price and historical performance?","url":"https://hygiea.tech/knowledge/what_is_the_current_omnicell_stock_price_and_historical_performance.php","description":"Omnicell Inc. shares have endured a severe valuation contraction, trading approximately forty-two percent below fair value as of early August 2026...","datePublished":"November 21, 2026","author":{"@type":"Person","name":"hygiea.tech"},"mainEntity":{"@type":"Question","name":"What is the current Omnicell stock price and historical performance?","acceptedAnswer":{"@type":"Answer","text":"## Omnicell Stock Price Snapshot Omnicell Inc. shares have endured a severe valuation contraction, trading approximately forty-two percent below fair value as of early August 2026. This steep decline follows a broader market slump that erased roughly seventy-eight percent of the stock’s price since late September. Despite this heavy depreciation, analysts at Zacks Premium identified the healthcare technology firm as a strong value candidate in mid-November. The publicati..."}}}
```
